![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » NIAID Stops COVID-19 Trial Enrollment Over Adverse Events
NIAID Stops COVID-19 Trial Enrollment Over Adverse Events
October 1, 2020
The National Institute of Allergy and Infectious Diseases has stopped enrolling severely ill COVID-19 patients in a phase 3 trial of Merck’s Rebif (interferon beta-1a) with Gilead Sciences’ remdesivir because of serious adverse events.
An interim review of safety data found more adverse events among patients on high-flow oxygen/non-invasive mechanical ventilation who received Rebif vs. those who did not receive the drug.
There were no concerns among patients who had less severe COVID-19, and the trial will continue to enroll patients on low-flow oxygen and those not requiring supplemental oxygen.
Upcoming Events
-
21Oct